Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK44459 in Idiopathic Pulmonary Fibrosis
NCT06764862Phase 2Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HSK44459 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Change from baseline in forced vital capacity at 12 weeks. Started Jan 2025; status: completed.
02
Drugs
HSK44459
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06764862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764862.